Elevance Health stock sets October 21 earnings date

Published on 10/05/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elevance Health stock was trading at USD 387.67 on October 5, while Q2 revenue reached USD 49.83 billion. Analysts list a USD 440.90 average target.

Modernes Krankenhaus-Campus mit Glasfassade und Patienten im Eingangsbereich — Elevance Health Krankenversicherungs-Campus US2855211023 zeigt modernen Gebäudeeingang mit weitläufiger Grünanlage unter blauem Himmel, Illustration mit AI erstellt.

Elevance Health (ISIN US0367521038) was trading at USD 387.67 on the NYSE at 10:40 a.m. ET on October 5, 2026, up USD 1.24 or 0.32 percent from the prior close. The immediate company date is clearer: Business Wire reported on October 5 that Elevance Health will release third-quarter 2026 results on October 21, 2026, before management discusses the figures and outlook at 8:30 a.m. ET.

October 21 sets the next test

The scheduled release puts medical-cost trends and full-year guidance back at the center of the stock story. The company will publish results at 6:00 a.m. ET, followed by the conference call 2.5 hours later, creating a defined checkpoint for its 2026 earnings trajectory.

Elevance Health's second-quarter numbers provide the latest operating baseline. According to MarketBeat, Q2 2026 revenue was USD 49.83 billion, up 0.8 percent year over year, while earnings per share reached USD 7.45 versus a USD 6.21 consensus estimate. The USD 1.24 beat gives investors a concrete benchmark for the next report.

Guidance keeps the margin debate alive

Elevance Health reaffirmed full-year 2026 adjusted earnings guidance of at least USD 27.00 per diluted share in its September 10 filing, according to StockTitan. The same update retained benefit expense ratio guidance of 90.2 percent plus or minus 50 basis points, making utilization and cost control central measures for the October report.

The latest guidance also separates reported and adjusted performance. Full-year shareholders' earnings guidance stands at least USD 20.10 per diluted share, including USD 6.90 per share of net unfavorable items, while the adjusted figure excludes those items.

Analysts see room above USD 387.67

MarketBeat lists a Moderate Buy consensus based on 15 Buy ratings and eight Holds from 23 analysts. Its average price target is USD 440.90, which the outlet calculated as 14.0 percent above the USD 386.66 October 2 closing price.

That target sits below the 52-week high of USD 436.24 only after the stock has already recovered from its USD 274.84 low. The valuation discussion therefore depends on whether the October results confirm earnings progress while the benefit expense ratio remains within guidance.

Elevance Health stock holds near USD 388

Elevance Health stock was last at USD 387.67 on the NYSE on October 5, 2026, with a market capitalization of USD 84.1 billion and volume of 83,171 shares at the quoted time.